Introduction To The RUNX1-FPD Sirolimus Clinical Study
1pm PT / 3pm CT / 4pm EST
Learn more about a new clinical trial for RUNX1-FPD patients which will evaluate the safety and tolerability of a medicine called sirolimus, also known as rapamycin.
Sirolimus is an immunosuppressant that can reduce inflammation by blocking a signaling pathway called mTORC1. It is being tested because scientists found that mTORC1 is elevated in the bone marrow of RUNX1-FPD patients.
Dr. Courtney DiNardo, the study’s principal investigator, will provide an overview of the trial’s objectives, discuss the eligibility requirements for participation, and respond to questions from attendees.
